These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6197984)

  • 1. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.
    Mikhailidis DP; Barradas MA; Mikhailidis AM; Magnani H; Dandona P
    Br J Clin Pharmacol; 1984 Jan; 17(1):43-8. PubMed ID: 6197984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
    Burgess JK; Chong BH
    Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation.
    Bertelé V; Roncaglioni MC; Donati MB; de Gaetano G
    Thromb Haemost; 1983 Apr; 49(2):81-3. PubMed ID: 6346573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of five commercial heparin preparations on the collagen induced platelet aggregation (author's transl)].
    Kronik G; Deutsch E
    Blut; 1977 Nov; 35(5):363-72. PubMed ID: 72575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
    Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
    Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.
    Messmore HL; Griffin B; Fareed J; Coyne E; Seghatchian J
    Ann N Y Acad Sci; 1989; 556():217-32. PubMed ID: 2472085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelets of patients with peripheral arterial disease demonstrate a hypersensitive response to heparin.
    Reininger CB; Greinacher A; Eibl-Eibesfeldt B; Lasser R; Steckmeier B; Schweiberer L
    Int Angiol; 1996 Sep; 15(3):207-14. PubMed ID: 8971577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of heparin and heparinoids on platelet aggregation.
    Cepelák V; Roubal Z; Zemanová I; Opatrný K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):750-60. PubMed ID: 6083950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease.
    Mikhailidis DP; Barradas MA; Jeremy JY; Gracey L; Wakeling A; Dandona P
    Eur J Clin Invest; 1985 Dec; 15(6):313-9. PubMed ID: 3938401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI2): studies on mechanism.
    Saba SR; Saba HI
    Am J Hematol; 1985 Oct; 20(2):97-105. PubMed ID: 3898823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222).
    Barradas MA; Mikhailidis DP; Epemolu O; Jeremy JY; Fonseca V; Dandona P
    Br J Haematol; 1987 Dec; 67(4):451-7. PubMed ID: 2447931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a natural heparinoid with sodium and calcium heparin for their effect on the inhibitor of activated factor X.
    Mannucci PM; di Santo C; Franchi F
    Experientia; 1976 Nov; 32(11):1478-80. PubMed ID: 62674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).
    Mikhailidis DP; Fonseca VA; Barradas MA; Jeremy JY; Dandona P
    Br J Clin Pharmacol; 1987 Oct; 24(4):415-24. PubMed ID: 3689624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heparin-associated thrombocytopenia: successful therapy of patients after prospective selection of a compatible heparinoid with the heparin-induced platelet activation test].
    Greinacher A; Michels I; Mueller-Eckhardt C
    Beitr Infusionsther; 1992; 30():408-12. PubMed ID: 1284747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation.
    Eldor A; Weksler BB
    Thromb Res; 1979; 16(5-6):617-28. PubMed ID: 392805
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
    Kikta MJ; Keller MP; Humphrey PW; Silver D
    Surgery; 1993 Oct; 114(4):705-10. PubMed ID: 7692613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.